Navigation Links
Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy

MINNEAPOLIS--(BUSINESS WIRE)--Apr 26, 2007 - A new study published in the current issue of the Journal of Child Neurology indicates that a treatment from Medtronic, Inc. (NYSE:MDT), for spasticity in children with cerebral palsy improves their quality of life and is cost-effective compared to other established cost-effective treatments. The findings of this Medtronic-sponsored study should expand access to the treatment, known as Medtronic ITB Therapy(SM) (Intrathecal Baclofen Therapy).

Cerebral palsy affects an estimated 764,000 people in the United States, according to United Cerebral Palsy, with approximately 8,000 babies and 1,200 to 1,500 preschool-age children diagnosed with the condition each year. Caused by damage to one or more areas of the developing brain, cerebral palsy is characterized by an inability to control motor function fully, particularly muscle control and coordination.

The most common form of cerebral palsy involves spasticity - tight, stiff muscles that make coordinated movement (especially of the arms and legs) difficult or uncontrollable. Up to 80 percent of children with cerebral palsy develop spasticity, which can be painful and limit functional ability for the patient, and tax the patient's family physically, emotionally, and financially.

Medtronic ITB Therapy, which uses the company's SynchroMed(R) implantable infusion system to deliver a muscle relaxant directly to the fluid-filled area surrounding the spinal cord, can effectively reduce severe spasticity with fewer side-effects than oral medication. By reducing spasticity, ITB Therapy may also improve function, quality of life, and ease of care.

Despite the treatment's well-demonstrated clinical efficacy, ITB Therapy remains underused - in large part because of concerns about the cost of the pump and the surgery to implant it.

"The cost of ITB Therapy should not prevent pediatric patients with spastici
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)... 29, 2014   ... will present data from a Phase I clinical trial ... or stop Parkinson,s disease progression. The Michael J. Fox ... and will discuss the impact of the results for ... Thursday, July 31, 2014       ...
(Date:7/29/2014)... 2014  Drug development for hepatitis C virus ... and the intense need for curative therapy in ... underway as the market moves away from protease ... interferon-free oral therapies. Logo - ... blockbuster Sovaldi is the first of these novel ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... May 2, 2012 Janssen Research & Development, LLC, ... Drug Applications (sNDAs) to the U.S. Food and Drug ... ® (rivaroxaban), an oral anticoagulant, to treat patients ... and prevention of recurrent venous thromboembolism (VTE). ...
... Official journal of the American Association for ... of scientific, technical and medical information products and services, announces ... American Association for Geriatric Psychiatry (AAGP) to publish ... AJGP ) beginning in January 2013. "We are ...
Cached Medicine Technology:Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 2Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 3
(Date:7/29/2014)... 2014 As testosterone treatment lawsuits ( ... Liebhard LLP notes that a new study is questioning ... 2 diabetes. The research, which was published online by ... 30th, involved 88 men who suffered from Type 2 ... male symptoms and erectile dysfunction. Roughly half of the ...
(Date:7/29/2014)... Gerontological Society of America (GSA) the nation,s ... has chosen Barbara J. Bowers, PhD, RN, FAAN, ... of the Task Force on Minority Issues in Gerontology ... annually to an individual who has exemplified outstanding commitment ... of aging. , The award presentation will take place ...
(Date:7/29/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... N. Gitlin, PhD, of the Johns Hopkins University Schools ... the M. Powell Lawton Award. , This distinguished ... led to an innovation in gerontological treatment, practice or ... public policy change that has led to some practical ...
(Date:7/29/2014)... July 29, 2014 Outsourced coding ... tripling in the number of hospitals contracting for ... 2015 deadline, according to the recently published Black ... leaders, found in the reports “Top Ranked Clinical ... now outsource Clinical documentation audit, review and programming. ...
(Date:7/29/2014)... group of new materials capable of repelling bacteria ... a combined 2m to find out why. ... a significant reduction in hospital infections acquired through ... of hospital patients across the globe. , Morgan ... of Pharmacy and Paul Williams, Professor of Molecular ...
Breaking Medicine News(10 mins):Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2Health News:Gitlin earns GSA's 2014 M. Powell Lawton Award 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 3Health News:Bacteria resistant materials -- £2m to get the 'inside' story 2Health News:Bacteria resistant materials -- £2m to get the 'inside' story 3
... tubing production capacity by 50% , ... West Chester, ... Medical has announced the expansion of its Precious Metal tubing production ... and marker bands. Precious metals - Platinum, in particular - ...
... that state policies meant to limit minors, indoor tanning ... 15, 2009 issue of CANCER , a peer-reviewed ... that additional efforts are needed to reduce indoor tanning ... an individual,s risk of developing skin cancer, a number ...
... , PRESS CONFERENCE MONDAY DECEMBER 8, 20089:30AM ... YORK, Dec. 7 , , ... American high school students reaches its grand finale as the national winners ... $100,000 Grand Prize scholarships will be awarded to one individual and one ...
... Immunization Week runs Dec. 8 - 14 , ... amounts of flu vaccine available, the Pennsylvania Department of Health today ... hockey fans attending the Hershey Bears-Norfolk game at the Giant Center. ... comes down with the flu every year, resulting in 8,400 hospitalizations ...
... be linked to abnormalities in a person,s body clock ... published today in the journal Nature Genetics . ... than normal blood sugar levels could partly be tackled ... College London, the French National Research Institute CNRS, Lille ...
... Minn. - A new Mayo Clinic study found that ... children with epilepsy who have achieved seizure-freedom while on ... at high risk of subsequently developing intractable epilepsy. The ... the American Epilepsy Society,s annual meeting in Seattle. , , ...
Cached Medicine News:Health News:Johnson Matthey Medical Announces Expansion 2Health News:State policies have little effect on reducing minors' indoor tanning use 2Health News:$100,000 Winners of Nation's Premier High School Science Competition to be Announced 2Health News:PA Department of Health Kicks Off National Influenza Immunization Week With Free Flu Shots at Hershey Bears Game 2Health News:Body clock linked to diabetes and high blood sugar in new study 2Health News:Body clock linked to diabetes and high blood sugar in new study 3Health News:Mayo Clinic finds it generally safe to withdraw anti-seizure medication in children with epilepsy 2
... The Medison SonoAce 9900 ... NT2000 based ultrasound system, ... that is DICOM compatible, ... including general imaging, obstetrics, ...
Premium Full Color Digital Ultrasound...
... latest technologies to help expand your diagnostic ... advancements increase system utility and provide you ... of even the smallest details. And with ... delivery and expedite a higher quality of ...
AngioSpeed V series, it is an Angiography system designed for vascular treatment in various radiological regions, cardiology, and neurology. SHIMADZU brings you a single system with all units fused t...
Medicine Products: